Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 5,319 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Continuous Dose Clear all
Active, not recruiting Phase 3 Interventional Results available

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00602641
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Prednisone, Quality-of-Life Assessment, Thalidomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
389
States / cities
Mobile, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 255 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 12:19 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Dexmedetomidine Sedation With Third Molar Surgery

NCT01017237
View directory record Official record
Conditions
Anesthesia
Interventions
Dexmedetomidine, Midazolam, Ketamine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 30 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 1 Interventional

Hydroxychloroquine + Vorinostat in Advanced Solid Tumors

NCT01023737
View directory record Official record
Conditions
Malignant Solid Tumour
Interventions
Hydroxychloroquine, Vorinostat
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
16 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 31, 2026, 12:19 PM EDT
Recruiting Phase 2 Interventional

Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism

NCT07091279
View directory record Official record
Conditions
Autism Spectrum Disorder, Challenging Behaviour, Aggression, Severe Disruptive Behaviour Disorders, Self-injury
Interventions
Propranolol, Placebo
Drug
Lead sponsor
Jeremy Veenstra-vanderweele
Other
Eligibility
12 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Staten Island, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

NCT02889562
View directory record Official record
Conditions
Coronary Artery Bypass Grafting, Postoperative Atrial Fibrilation, Stroke, Systemic Embolism, Deep Venous Thrombosis
Interventions
Apixaban, Warfarin
Drug
Lead sponsor
Sanford Health
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 1 Interventional Results available

Phase I Study of APX005M in Pediatric Central Nervous System Tumors

NCT03389802
View directory record Official record
Conditions
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS), Diffuse Intrinsic Pontine Gliomas (DIPG), Medulloblastoma
Interventions
APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
Biological
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
1 Year to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 3 Interventional

Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

NCT00369837
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Montgomery, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

NCT00200161
View directory record Official record
Conditions
Glioblastoma, Gliomas
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 1 Interventional Results available

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

NCT00965731
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Erlotinib, PF-02341066
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • Fort Lauderdale, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 3 Interventional Results available

A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium

NCT00865202
View directory record Official record
Conditions
Post-operative Delirium
Interventions
L-tryptophan supplementation, placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 31, 2026, 12:19 PM EDT
Terminated Phase 1Phase 2 Interventional

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

NCT05860296
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Interventions
SLC-391, pembrolizumab
Drug · Biological
Lead sponsor
SignalChem Lifesciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation

NCT01044862
View directory record Official record
Conditions
Pregnancy, Unexplained Infertility
Interventions
Letrozole (aromatase inhibitor), Clomiphene Citrate, Follicle Stimulating Hormone (gonadotropin)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 4 Interventional Results available

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

NCT04006288
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Prasugrel, ticagrelor, aspirin, rivaroxaban
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 31, 2026, 12:19 PM EDT
Terminated Phase 2 Interventional Results available

Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

NCT00281827
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, thalidomide, conventional surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
Minneapolis, Minnesota • Robbinsdale, Minnesota • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 1Phase 2 Interventional

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01665794
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Carfilzomib, dexamethasone, Daratumumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 4 Interventional Results available

Menopur Mixed Protocol

NCT01417195
View directory record Official record
Conditions
Infertility
Interventions
Bravelle, Menopur
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Lone Tree, Colorado • Clearwater, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 1 Interventional Results available

Understanding Dexmedetomidine in Neonates After Open Heart Surgery

NCT00576381
View directory record Official record
Conditions
Tetrology of Fallot, Heart Ventricle, Hypoplastic Left Heart
Interventions
Dexmedetomidine
Drug
Lead sponsor
Athena Zuppa
Other
Eligibility
1 Hour to 30 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2013 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Not applicable Interventional Results available

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?

NCT01054599
View directory record Official record
Conditions
Epilepsy
Interventions
Memantine, Sugar Pill
Drug · Other
Lead sponsor
American Academy of Neurology
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 31, 2026, 12:19 PM EDT
Recruiting Phase 2 Interventional

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

NCT06111781
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix 120 MG [Orgovyx], SBRT standard of care radiotherapy treatment
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
New Haven, Connecticut • Lebanon, New Hampshire • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy

NCT00587067
View directory record Official record
Conditions
Hepatic Cancer
Interventions
FLOXURIDINE
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 3 Interventional Results available

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

NCT03189719
View directory record Official record
Conditions
Esophageal Neoplasms
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
12
States / cities
West Los Angeles, California • Chicago, Illinois • Westwood, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 31, 2026, 12:19 PM EDT
Recruiting Phase 3 Interventional

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328
View directory record Official record
Conditions
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
332
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 12:19 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer

NCT02508636
View directory record Official record
Conditions
Prostatic Neoplasms, Pelvic Nodal
Interventions
Enzalutamide, Leuprolide, Intensity-Modulated Radiation Therapy
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 31, 2026, 12:19 PM EDT
Completed Phase 2 Interventional

Emergency Department-Initiated Buprenorphine Validation Network Trial

NCT04225598
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
CAM2038, Buprenorphine Sublingual Product
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Oakland, California • San Leandro, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 31, 2026, 12:19 PM EDT